The US oncolytic virus therapy market is estimated to grow at a CAGR of around 17% during the forecast period. The market growth is attributed to the established research environment for various biotechnologies, the presence of major healthcare providers and growing healthcare investment in the US. Moreover, a growing number of cancer patients is augmenting the demand for oncolytic virus therapy. T?Vec (talimogene laherparepvec), is a recently approved oncolytic virus drug in the US and Europe. It is the second-generation oncolytic drug armed with GM-CSF to cure cancer, approved in 2015.

Research is undergoing other oncolytic virus drugs to cure cancer patients suffering from brain tumors along with breast, lung, liver and bladder cancer. There are other oncolytic virus drugs being researched which include JX?594 (pexastimogenedevacirepvec) for hepatocellular carcinoma, GM?CSF?expressing adenovirus CG0070 for bladder cancer, and Reolysin (pelareorep), a wild?type variant of reovirus for head and neck cancer.

Request a Free Report on Sample of US Oncolytic Virus Therapy Market @ https://www.omrglobal.com/request-sample/us-oncolytic-virus-therapy-market

The US oncolytic virus therapy market is segmented on the basis of product and application. Based on the product, the market is segmented into HSV-based oncolytic viruses, adenoviruses-based oncolytic viruses, vaccinia virus-based oncolytic viruses, vesicular stomatitis virus-based oncolytic viruses, Newcastle disease oncolytic viruses, and other oncolytic viruses. HSV-based oncolytic virus therapy held the highest market share of over 94% in 2018, whereas, adenoviruses-based therapy held the rest. Based on the application, the market is segmented into prostate cancer, breast cancer, ovarian cancer, melanoma, and others. In 2018, the melanoma application held the largest market share of around 95%.

A full Report of US Oncolytic Virus Therapy Market at https://www.omrglobal.com/industry-reports/us-oncolytic-virus-therapy-market

The report covers the analysis of several players operating in the US oncolytic virus therapy market. Some of the major players include Bristol-Myers Squibb Company, Abbvie Inc., Janssen Biotech Inc., Cold Genesys Inc., Cynvec LLC, and others. In December 2018, Bristol-Myers Squibb Company signed an agreement with PsiOxus Therapeutics, Ltd. to grant the company rights to NG-348, a pre-clinical stage, an armed oncolytic virus which addresses solid tumors. PsiOxus developed tumor-targeted delivery with oncolytic viruses’ platform, to target cancer and enable more patients to respond to treatment. The company has continued the study and development of immuno-oncology, which includes development in NG-348, in order to understand the potential of oncolytic viruses to boost checkpoint blockade in several types of cancer.

US Oncolytic Virus Therapy Market Segmentation

By Product

• HSV-Based Oncolytic Virus
• Adenoviruses-Based Oncolytic Virus
• Vaccinia Virus-Based Oncolytic Virus
• Vesicular Stomatitis Virus-Based Oncolytic Virus
• Newcastle Disease Virus- Based Oncolytic Virus
• Others

By Application

• Prostate Cancer
• Breast Cancer
• Ovarian Cancer
• Melanoma
• Others

Company Profiles

• AbbVie, Inc.
• Amgen, Inc.
• Bristol-Myers Squibb Company
• Cold Genesys Inc.
• Creative Biolabs Inc.
• Cynvec LLC
• DNAtrix Inc.
• Genelux Corp.
• Janssen Biotech Inc.
• Merck & Co., Inc.
• Oncolytic Biotech, Inc.
• Oncorus Inc.
• Sorrento Therapeutics Inc.
• Vyriad

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/us-oncolytic-virus-therapy-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com/

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. AnuragTiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 780-304-0404
Visit for https://www.omrglobal.com/industry-reports/oncolytic-virus-therapy-market